Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1248-1255

  Delaloge, S ^a   Yovine, A ^a   Taamma, A ^a   Riofrio, M ^a   Brain, E ^a   Raymond, E ^a   Cottu, P ^a   Goldwasser, F ^a   Jimeno, J ^a   Misset, J L ^a   Marty, M ^a   Cvitkovic, E ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTHRACYCLINE ANTIBIOTIC AGENT; TRABECTEDIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NEUTROPENIA; OSTEOSARCOMA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; THROMBOCYTOPENIA; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

EID: 0035281734     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1248     Document Type: Article

References (39)

1. Sarcomas of the soft tissues and bone
2. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
3. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
4. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients
5. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma
6. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
7. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
8. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas
9. High-dose ifosfamide in bone and soft tissue sarcomas: Result of phase II and pilot studies - Dose-response and schedule dependence
10. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group
11. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic
12. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
13. P53 abnormalities influence modulation of MDR in primary cultures of adult soft tissue sarcoma overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
14. Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities
15. Advanced soft tissue sarcoma: How many more trials with anthracyclines and ifosfamide?
16. Sarcomas of the soft tissues and bone
17. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata
18. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin-743, a potent antitumor compound from the Caribbean tunicate Ecteinascidin turbinata
19. Mode of action of ecteinascidin 743, a natural marine compound with antitumoral activity
20. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
21. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDRI activation
22. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
23. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743)
24. High antitumor activity of ET-743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer
25. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
26. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
27. Exploratory evaluation of the potential predictors for dose-limiting toxicities (DLTs) in patients treated with ecteinascidin-743 (ET-743) as a 2-h intravenous (iv) infusion every 3 weeks and its relationship to pharmacokinetics (PK)
28. Reporting results of cancer treatment
29. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult
30. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma
31. Phase II study of paclitaxel in patients with soft tissue sarcoma
32. Navelbine shows activity in previously treated sarcoma patients: Phase II results from MGH/DANA Farber/Partner's Cancer Care Study
33. SWOG 9518: Phase II trial of continuous infusion topotecan in patients with advanced soft tissue sarcomas (STS)
34. Phase II study of irinotecan (CPT-II) in relapsed or refractory soft tissue sarcoma (STS)
35. Phase II study of temozolomide in advanced sarcomas
36. Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
37. Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients (Pts) with advanced sarcoma: A Mayo Cancer Center Study
38. Phase II study of ET-743 in advanced soft tissue sarcoma (ASTS) in adults: A STBSG-EORTC trial
39. Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: Summary of 3 US-based phase II trials